CME Corner

Program Detail

Release Date: November-22-19
Credit Expiration Date: November-22-20


Stuart Russell, MD
Professor of Medicine
Duke University School of Medicine
Regional Director of Heart Failure
Duke University School of Medicine
Durham, NC

Nisha Gilotra, MD
Assistant Professor of Medicine
Director, Heart Failure Bridge Clinic
Johns Hopkins School of Medicine

Credit Hours



Mobile + Online on RealCME

Program Description

Quality performance measures for patients hospitalized with HF substantiate that there is room to improve the management and outcomes in this population. Recognizing that continuing medical education (CME) “supports the improvement of knowledge, confidence, and clinical performance among healthcare providers,” a CME program focused on improving HF readmission quality measures may have a substantial impact in helping improve outcomes and lower health care costs for this patient population. Purdue University College of Pharmacy - Office of Continuing Education (Purdue) and MCM Education (MCM) in collaboration with RealCME, propose an online continuing medical education (CME) initiative, Preventing Hospital Readmissions in Heart Failure with Quality-focused Learning. The goal of the proposed curriculum is to provide cardiologists, pharmacists, nurse practitioners, and other clinicians guidance on establishing and implementing an evidence-based plan to reduce hospital readmissions in patients with HF.

Program Developer/Facilitator


Target Audience

Cardiologists, emergency medicine physicians, internists, NPs, PAs, pharmacists, and other clinicians involved in the care of patients with HF.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Define performance measures from NQF and CMS relevant for HF readmissions.
  2. Identify patients with HF who are at greatest risk of health complications and hospitalizations.
  3. Develop a coordinated multidisciplinary plan for interventions that have been shown to be effective in reducing 30-day hospital readmissions in patients with HF.
  4. Identify data available in your clinical setting and metrics your clinical team will use to evaluate performance improvement in HF hospital readmissions.
  5. Describe the process to implement interventions for performance improvement in reducing 30-day readmissions in patients with HF.
  6. Evaluate the effectiveness of interventions implemented to reduce 30-day readmissions for patients with HF.


All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of MCM Education and Purdue University College of Pharmacy have no relationships to disclose.

Dr. Russell has nothing to disclose.

Dr. Gilotra discloses the following:
Consultant: scPharmaceuticals
Grants/Research Support: Intracellular Therapeutics

Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.

Credit Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation:
Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Grant Supporter: Novartis Pharmaceuticals Corporation

American Board of Internal Medicine Maintenance of Certification (from ABIM):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Pharmacist Accreditation Statement:
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-19-099-H01-P, 0.5 contact hours (0.05 CEU).

Commercial Support Statements

This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Certificate Fee



© 2019 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Purdue University, or Novartis Pharmaceuticals Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu